Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01371734 · ClinicalTrials.gov registry record · Phase 3

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

A Phase 3 study of Major Depressive Disorder, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
363
Enrollment target
20
Study locations

NCT01371734 is a Phase 3 study of Major Depressive Disorder that has completed, run by Pfizer. The registered enrollment target is 363 participants, roughly in line with the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target. The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01371734, a Phase 3 study of Major Depressive Disorder, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
363 participants
Enrollment target
20
Study locations

Study Summary

This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).

Conditions Studied

Major Depressive Disorder

Interventions

  • DRUG Placebo
  • DRUG Desvenlafaxine Succinate Sustained-Release

Study Locations (20)

Florida

  • SJS Clinical Research, Inc. - Destin
  • Sarkis Clinical Trials - Gainesville
  • Clinical Neuroscience Solutions - Jacksonville
  • Medical Research Group of Central Florida - Orange City
  • Millenia Psychiatry & Research, Inc. - Orlando
  • Janus Center for Psychiatric Research - West Palm Beach

Connecticut

  • Bliss Basement Pharmacy - Hartford Hospital - Hartford
  • Institute of Living/Hartford Hospital - Hartford
  • Institute of Living - Hartford

Alabama

  • Children's Hospital of Alabama Laboratory - Birmingham
  • The University of Alabama at Birmingham, Office of Psychiatric Research - Birmingham

Illinois

  • Capstone Clinical Research - Libertyville
  • AMR-Baber Research Inc. - Naperville

Louisiana

  • Louisiana State University Health Sciences Center-Psychopharmacology Research Clinic - Shreveport
  • Drug:University Health Shreveport Outpatient - Shreveport

Arizona

  • Center for Advanced Improvement - Tucson

California

  • Sun Valley Research Center - Imperial

Colorado

  • MCB Clinical Research Centers - Colorado Springs

Trial Details

FieldValue
Enrollment Target 363 participants
Start Date 2011-08
Est. Completion 2015-09
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01371734

The ClinicalTrials.gov registry entry for NCT01371734 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 363 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01371734 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Connecticut, Alabama.

Frequently Asked Questions

What is clinical trial NCT01371734 about?

NCT01371734 is a clinical study titled "A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD". This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).

What is the current status of trial NCT01371734?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 363 participants. The study started on 2011-08. Estimated completion is 2015-09.

What conditions does trial NCT01371734 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT01371734?

The interventions under investigation include: Placebo (DRUG), Desvenlafaxine Succinate Sustained-Release (DRUG).

Who is sponsoring clinical trial NCT01371734?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01371734 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Major Depressive Disorder

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.